-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
FDA/CDER-AACR-IASLC-IASLC Workshop
-
Oncology Trials Could Benefit From Increased Data on Tobacco Use
By Leah Lawrence Posted: June 24, 2020 As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially and during the study, should be a required data element for all prospective clinical studies and that these studies should consider designs that could also determine the most effective…
-
IASLC’s Inaugural Mesothelioma Meeting Sets Baseline for Strategic Approach to Patient Care
Posted: November 15, 2019 As a rare orphan disease, mesothelioma research has been slowed by a lack of eligible patients for trials and by a dearth of resources. Because of these hurdles, agreement among oncologists and researchers in the field regarding strategic priorities is necessary. The IASLC 2018 Mesothelioma Meeting held this past July in…
View ILCN Archives
Provider Resources
Popular Articles